Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study

AIMS: To provide real‐world data on the addition of basal insulin (BI) in people with type 2 diabetes mellitus (PWD2) suboptimally controlled with glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy. However, real‐world data on the addition of BI to GLP‐1RA therapy are limited. MATERIALS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Timothy S., Gill, Jasvinder, Jones S., Merwyn, Shenoy, Laxmi, Nicholls, Charlie, Westerbacka, Jukka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286657/
https://www.ncbi.nlm.nih.gov/pubmed/35491520
http://dx.doi.org/10.1111/dom.14739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286657/
https://www.ncbi.nlm.nih.gov/pubmed/35491520
http://dx.doi.org/10.1111/dom.14739

Ejemplares similares